faricimab: Clinical Trials

10 trials of faricimab, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

7 completed, 1 active not recruiting, 1 not yet recruiting, 1 unknown. 10 Phase 2, 1 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 210Completed 7, Active not recruiting 1, Not yet recruiting 1, Unknown 1
Phase 11Completed 1
Phase 31Unknown 1

Follow faricimab: new trials by email Literature Review of faricimab trials Research Report on faricimab

Trials (filtered) newest first · largest first

All 10 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Faricimab for Chronic Central Serous Chorioretinopathy: A Randomized Sham-Controlled Trial
Faricimab, Sham - Central Serous Chorioretinopathy (CSC)
Phase 2Not yet recruitingSingapore National Eye Centre502026-12-012026-07-02
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema(DME)
IBI302, Faricimab - Diabetic Macular Oedema
Phase 2Active not recruitingInnovent Biologics Technology Limited (Shanghai R&D Center)1502025-04-242026-05-27
Intravitreal Faricimab in Patients With Refractory Macular Edema
Faricimab Injection - Age-Related Macular Degeneration
Phase 2CompletedUniversity of Baghdad432024-09-102025-07-30
Evaluation of Therapeutic Efficacy of Faricimab for Clinical AMD, DME, and RVO Patients
Faricimab - Age-Related Macular Degeneration, Diabetic Macular Edema
Phase 2 / Phase 3UnknownSecond Affiliated Hospital, Zhejiang University, School of Medicine302024-03-012024-08-27
Safety and Efficacy of Faricimab in Patients With NPDR
Faricimab - Non-Proliferative Diabetic Retinopathy
Phase 2CompletedGreater Houston Retina Research1792023-05-162026-03-20
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of RO7446603 Administered Alone or in Combination With Aflibercept or Faricimab in Participants With Diabetic Macular Edema
RO7446603, Aflibercept, Faricimab - Diabetic Macular Edema
Phase 1 / Phase 2CompletedGenentech, Inc.3882022-06-222026-06-23
A Study to Investigate Aqueous Humor and Multimodal Imaging Biomarkers in Treatment-Naïve Participants With Diabetic Macular Edema Treated With Faricimab
Faricimab - Diabetic Macular Edema
Phase 2CompletedHoffmann-La Roche992020-11-252026-06-15
Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration
Faricimab, Ranibizumab, Sham Procedure - Neovascularization, Choroidal, Macular Degeneration, Age-Related
Phase 2CompletedHoffmann-La Roche762017-01-272021-01-05
A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema
Faricimab, Ranibizumab - Diabetic Macular Edema
Phase 2CompletedHoffmann-La Roche2292016-04-272020-09-25
A Proof-of-Concept Study of Faricimab (RO6867461) in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD)
Faricimab, Ranibizumab, Sham Procedure - Choroidal Neovascularization
Phase 2CompletedHoffmann-La Roche2732015-08-112020-11-12

Conditions studied

Macular Degeneration (3)  ·  Choroidal Neovascularization (2)  ·  Central Serous Chorioretinopathy (1)  ·  Retinal Vein Occlusion (1)

Sponsors

Hoffmann-La Roche (4)  ·  Genentech, Inc. (1)  ·  Greater Houston Retina Research (1)  ·  Innovent Biologics Technology Limited (Shanghai R&D Center) (1)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (1)  ·  Singapore National Eye Centre (1)  ·  University of Baghdad (1)

Countries

United States (6)  ·  China (3)  ·  Argentina (1)  ·  Canada (1)  ·  Germany (1)  ·  Iraq (1)  ·  Italy (1)  ·  Poland (1)  ·  Puerto Rico (1)  ·  United Kingdom (1)

Top investigators

Duaa J Kadhim (1)  ·  Panpan Ye, doctor (1)

Results publications

PMID 30905643, PMID 32729888, PMID 32729897, PMID 34201045, PMID 37422192, PMID 37868796, PMID 38758639, PMID 41587134, PMID 42058170